# Elekta account plan

> Elekta is a Stockholm-listed precision radiotherapy group with SEK 16,718 M net sales in FY 2025/26 and about 7,500 devices installed in 130+ countries.

## At a glance

Elekta, based in Stockholm and listed on Nasdaq Stockholm, develops, makes and sells hardware, software and services for precision radiotherapy, radiosurgery and brachytherapy: linear accelerators (Harmony, Evo, Unity MR-Linac), Leksell Gamma Knife, Flexitron afterloaders and the Elekta ONE oncology software. Its installed base is about 7,500 devices and software solutions at 2,500 clinics in more than 130 countries. In FY 2025/26 (May 2025-April 2026) net sales were SEK 16,718 M, with an adjusted EBIT margin of 12.3% but a net income of SEK -517 M after impairments and restructuring charges; Solutions were 56% and Service 44% of sales. It had 4,102 employees at year-end, and founder Laurent Leksell chairs the board, holding 30.23% of votes. President and CEO is Jakob Just-Bomholt.

## Business units

- **Europe** (SEK 5,421 M FY 2025/26 net sales, 21.2% adjusted EBIT margin): Replacement-driven mature markets where about 1,000 of 3,900 linacs are 12-17 years old; Elekta grew share in the Nordics, the UK and Italy and leads in neuro and brachytherapy. Q1 2026/27 sales rose 5% at constant rates to SEK 1,202 M. The region is led by Arnaud Delhaye.
- **Americas** (SEK 4,461 M FY 2025/26 net sales (27% of group), 13.3% adjusted EBIT margin): North America waited for Elekta Evo's FDA clearance, received in January 2026, after which U.S. orders showed double-digit growth; Latin America keeps growing with greenfield capacity. Q1 2026/27 sales were SEK 1,088 M, +2% at constant rates. The region is led by Ardie Ermers.
- **China** (SEK 2,442 M FY 2025/26 net sales, 11.9% adjusted EBIT margin): Recovering since the anti-corruption campaign of mid-2023, with order intake up for three consecutive quarters; Elekta localizes products and supply chain, including Flexitron production. Q1 2026/27 sales fell 16% at constant rates to SEK 432 M. The region is led by Anming Gong.
- **APJ (Asia Pacific and Japan)** (SEK 2,239 M FY 2025/26 net sales, 10.8% adjusted EBIT margin): A market down on constrained healthcare budgets, including an Indonesian government tender, a Vietnamese anti-corruption clampdown and a slower Japanese recovery. Q1 2026/27 sales fell 12% at constant rates to SEK 414 M.
- **TIMEA (Türkiye, India, Middle East and Africa)** (SEK 2,154 M FY 2025/26 net sales, 3.2% adjusted EBIT margin): The lowest-margin region because of price pressure in Africa and India; Q1 2026/27 sales fell 4% at constant rates to SEK 401 M as Middle East conflicts delayed installations. Management expects it to be the fastest-growing region in FY 2026/27.

## Strategic priorities

- **Three-phase turnaround**: Reset and stabilize (completed), improve profitability (FY 2026/27), then innovation-driven growth; the new regional P&L operating model cut annualized costs by more than SEK 500 million and headcount to below 4,000.
- **Win in the U.S. and expand in China**: The U.S. is only 20% of revenue; Elekta targets mid-to-high single-digit revenue CAGR in the Americas over three years, and in China aims to keep leadership while deepening localization.
- **Focused innovation in adaptive radiotherapy**: R&D at about 10% of revenue on fewer core products, with a launch wave within 12 months: next-generation Iris imaging, real-time CT motion management, an integrated console, a 6D table and Unity Pro 30-minute MR-Linac slots.
- **Continuous COGS reduction and pricing**: Dual sourcing, cost-efficient suppliers, AI tools for field service engineers and simpler installation, plus a new pricing framework with floor ASPs and an expected price uplift of 2-3%.
- **FY 2028/29 mid-term targets**: Mid-single-digit sales CAGR in fixed currency, a 14-16% adjusted EBIT margin and free cash flow before dividends of about 10% of sales.

## Latest results

In Q1 2026/27 (May-July 2026) net sales fell to SEK 3,536 M (3,646), -2% at constant exchange rates: Solutions fell 9% while Services grew 5% with growth in all regions. Profitability jumped, with an adjusted gross margin of 42.6% (37.0) and adjusted EBIT of SEK 395 M, a margin of 11.2% (6.5); a US tariff refund of SEK 53 M added 150 basis points. Net income was SEK 261 M (106) and book-to-bill 1.11, driven by Elekta Evo. The FY 2026/27 outlook was reiterated: net sales +2-4% in constant currency and an adjusted EBIT margin of 12.5-13.5%.

## Investments and deals

- **R&D spend**: Gross R&D held at about 10% of revenue; continuous investments were SEK 1,072 M in FY 2025/26, mostly in the linac family and software.
- **EIB credit facility**: A EUR 100 M credit facility with the European Investment Bank for R&D project funding, signed on August 24, 2026, with up to 6 years maturity.
- **Portfolio clean-up**: Impairments of SEK 1,096 M in FY 2025/26, mainly discontinued R&D projects and SEK 235 M of goodwill from the Kaiku wind-down.
- **Croatia distributor assets**: Elekta acquired assets from its distributor in Croatia in June 2025.

## Challenges and risks

- **Growing slower than the market**: The CEO puts radiotherapy market growth at roughly 6% and says Elekta is "still not growing with the market"; Q1 2026/27 sales fell 2% at constant currency.
- **Competition and price pressure**: Siemens Healthineers (Varian) is the main competitor and United Imaging competes in China, where volume-based and centralized procurement add price pressure.
- **Order backlog quality**: A backlog review led to SEK 2.2 billion of cancellations and stricter order criteria such as prepayment, site readiness and delivery within three years.
- **Geopolitics, tariffs and currency**: Tariffs, sanctions and Middle East conflicts delayed installations in TIMEA; costs in GBP and CNY against USD revenue create currency exposure.
- **Cyber and data privacy**: The annual report lists data privacy and cyber attacks on healthcare data, including agentic AI, among its risks.

## What leadership says

> "This year is really about improving the underlying profitability of the company." — Jakob Just-Bomholt, President and CEO, Q1 2026/27 earnings call (27 August 2026)

> "We are still not growing with the market. That is highly unsatisfactory." — Jakob Just-Bomholt, President and CEO, Q1 2026/27 earnings call (27 August 2026)

> "is going to be a lifestyle. It's not a diet." — Jakob Just-Bomholt, President and CEO, On cost discipline, Capital Markets Day 2026 (17 June 2026)


## Where a supplier can help

- **COGS reduction and sourcing**: The continuous COGS reduction battle relies on dual sourcing and cost-efficient suppliers, an opening for component, manufacturing and procurement partners.
- **Field service productivity**: AI tools for field service engineers and simpler installation are part of the COGS programme, and Services grew in every region; service management and AI support tooling fit here.
- **U.S. commercial execution**: Winning in the U.S., where Elekta has only 20% of revenue and Evo orders are growing, calls for sales enablement, market intelligence and customer-facing tools.
- **Software and interoperability**: Focused innovation includes Elekta ONE, a new interoperability API and GPU-accelerated planning, which suits cloud, compute and software engineering partners.
- **Healthcare data security**: Cyber attacks on healthcare data, including agentic AI, are a named risk, supporting security and compliance offers for its connected software.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Elekta Annual Report 2025/26](https://ir.elekta.com/files/mfn/4fee6c42-f5eb-4dff-9601-c15ca8313eec/elekta-annual-report-2025-26.pdf)

Annual report · 2026-07-03

- Elekta (Stockholm, Nasdaq Stockholm) is a pure-play precision radiotherapy group: linear accelerators (Evo, Harmony, Unity MR-Linac), brachytherapy, Leksell Gamma Knife neurosurgery, Elekta ONE oncology software and services; installed base of about 7,500 devices at 2,500 clinics in more than 130 countries.
- FY 2025/26 (May 2025-April 2026): net sales SEK 16,718 M (18,016), -7% reported but +1% at constant exchange rates; Solutions 56% and Service 44% of sales; gross order intake SEK 17,441 M (19,718), -3% at constant rates.
- Adjusted EBIT margin 12.3% (11.6), the highest in five years, but reported EBIT fell to SEK 234 M (890) after impairments of SEK 1,096 M (mainly discontinued R&D projects and the Kaiku wind-down) and restructuring charges of SEK 421 M; net income SEK -517 M.
- A review of the order backlog led to SEK 2.2 billion of cancellations and a firmer interpretation of order criteria; cash flow after continuous investments rose to SEK 1,392 M (1,056); dividend kept at SEK 2.40.
- Three regions: EMEA 40% of sales (+7% at constant rates), APAC 33% (-2%), Americas 27% (-4%); Europe and Evo drove growth while North America waited for Evo's FDA clearance (received January 2026) and China recovered only in the second half.
- New CEO Jakob Just-Bomholt (ex-3Shape) set four Must-Win Battles: Simplify, Empower, Speed; Focused Innovation (adaptive radiotherapy); Win in the U.S. and expand in China; continuous COGS reduction. A new regional P&L operating model cut annualized costs by more than SEK 500 million.
- Guidance: FY 2026/27 net sales +2-4% in constant currency and an EBIT margin of 12.5-13.5%; mid-term targets for FY 2028/29 of mid-single-digit sales CAGR, 14-16% adjusted EBIT margin and free cash flow of about 10% of sales.
- Main competitor is Siemens Healthineers (Varian); United Imaging, Accuray, Bebig, ViewRay and RaySearch also compete; Elekta partners with Philips and GE Healthcare in imaging.
- Leadership renewed: CFO Klara Eiritz, CHRO Christina Raaschou, COO Rodolfo Velasco (from August 1); the Chief Commercial Officer role was eliminated as regions report to the CEO. Founder Laurent Leksell chairs the board and holds 30.23% of votes.

### [Elekta Interim report Q1 May-July 2026/27](https://ir.elekta.com/files/mfn/930687e5-0813-44e3-bee1-2ff6c64eada8/elekta-q1-report-2026-2027-eng.pdf)

Interim report · 2026-08-27

- Q1 2026/27 (May-July 2026) net sales SEK 3,536 M (3,646): -3% reported and -2% at constant exchange rates; Americas and Europe grew while APJ, China and TIMEA declined.
- Profitability jumped: adjusted gross margin 42.6% (37.0) and adjusted EBIT SEK 395 M (235), a margin of 11.2% (6.5); a US tariff refund of SEK 53 M added 150 basis points to the gross margin.
- Net income SEK 261 M (106), EPS SEK 0.69 (0.28); free cash flow before dividend and M&A SEK -266 M (-420); net debt SEK 3,576 M.
- Orders: book-to-bill 1.11 (1.05) driven by Elekta Evo; gross order intake SEK 3,910 M, +3% at constant rates; China order intake grew for the third consecutive quarter.
- New external reporting with five regions carrying fully loaded costs: Americas, China, Europe, TIMEA (Türkiye, India, Middle East, Africa) and APJ (Asia Pacific and Japan).
- The CEO says the first turnaround phase ("reset and stabilize") is complete; the focus this year is profitability through price, services and software growth and cost discipline.
- FY 2026/27 outlook reiterated: net sales +2-4% in constant currency and an adjusted EBIT margin of 12.5-13.5%; new COO Rodolfo Vasques completes the Executive Committee; EUR 100 M EIB R&D credit facility signed August 24.

### [Elekta Capital Markets Day 2026 - strategy, products, regions and targets (transcript)](https://stockanalysis.com/quote/sto/EKTA.B/transcripts/651258-cmd-2026/)

Executive talk · Jakob Just-Bomholt, President and CEO · 2026-06-17

- CEO Jakob Just-Bomholt calls it a turnaround: Elekta is "not trading at our full potential"; headcount fell from roughly 4,600 to 4,000, layers from nine to six, with savings of more than SEK 500 million.
- He sizes radiotherapy at about $7 billion (installed base 18,000 external-beam units); Elekta is number one in Neuro and Brachy, the only MR-Linac vendor, and a "clear number two" challenger in CT linacs and software.
- Targets: FY 2026/27 sales +2-4% at fixed currency and EBIT margin 12.5-13.5%; FY 2028/29 mid-single-digit sales CAGR, 14-16% EBIT margin and free cash flow of roughly 10% of sales (about SEK 2 billion).
- CPTO Christopher Busch commits to R&D at 10% of revenue and a launch wave within 12 months: next-generation Iris imaging, real-time CT motion management (prostate first), an integrated console and a 6D table; Unity Pro cuts MR-Linac slots to 30 minutes.
- U.S. (20% of revenue) is the growth bet: 30% solutions order growth last year, double-digit Evo orders and Varian flips; Americas head expects mid-to-high single-digit revenue CAGR over three years.
- Europe targets the 1,000 linacs aged 12-17 years up for replacement; China (about 40% share by revenue) expects 10% market growth to over 270 units in 2026 and a return to mid-single-digit growth.
- New pricing framework with floor ASPs and margins per product reviewed quarterly; expected price uplift of 2-3%; dividend of at least 50% of net income kept.

### [Elekta Q1 2026/27 earnings call (transcript)](https://stockanalysis.com/quote/sto/EKTA.B/transcripts/585714-q1-26-27/)

Executive talk · Jakob Just-Bomholt, President and CEO · 2026-08-27

- CEO Jakob Just-Bomholt: phase one of the three-phase turnaround (reset and stabilize) is complete; savings came in above expectation at more than SEK 500 million and this year is "about improving the underlying profitability".
- Q1 sales fell 2% at constant currency, below the 2-4% full-year guide, which he reiterated, expecting positive growth in Q2 and in the first half overall.
- The radiotherapy market grows "roughly 6%", so Elekta is "still not growing with the market. That is highly unsatisfactory."
- U.S.: Evo orders "develop as we planned"; "very solid double-digit growth" in U.S. orders; online adaptive for pelvis pending at the FDA; early reimbursement proposals indicate up to 5% uplift for freestanding centers and 2.5-3% for hospitals.
- China: weak Q1 installations from poor order intake a year earlier, but three consecutive quarters of order growth; market share in the mid-30s; about 25% of the market went through centralized bidding last year, where Elekta won more than 50%.
- CFO Klara Eiritz: adjusted gross margin 42.6% from service mix, pricing and lower costs; COGS inflation around 3%; a second US tariff refund of around $3 million expected in Q2.
- Headcount is now below 4,000 versus 4,500 half a year ago; R&D stays at roughly 10% of revenue; TIMEA is expected to be the fastest-growing region this year.

## Questions about Elekta

### What does Elekta do?

Elekta makes precision radiotherapy equipment, software and services, including linear accelerators, the Unity MR-Linac, Leksell Gamma Knife, brachytherapy afterloaders and the Elekta ONE oncology software.

### What is Elekta's revenue?

Net sales were SEK 16,718 M in FY 2025/26 (May 2025-April 2026), +1% at constant exchange rates. Q1 2026/27 net sales were SEK 3,536 M.

### How many employees does Elekta have?

Elekta had 4,102 employees at the end of FY 2025/26, and management says headcount is now below 4,000.

### What is Elekta's strategy?

A three-phase turnaround built on four Must-Win Battles: Simplify, Empower, Speed; Focused Innovation; Win in the U.S. and expand in China; and continuous COGS reduction, targeting a 14-16% adjusted EBIT margin by FY 2028/29.

### Who leads Elekta?

Jakob Just-Bomholt is President and CEO, Klara Eiritz CFO, and founder Laurent Leksell chairs the board.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
